The DOI matches its Crossref record.
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
Open accessAbstract
Plasma from 173 patients with HCV genotype 1 infection was analyzed for IP-10 levels prior to treatment with pegylated interferon-α-2a and ribavirin. Significantly lower IP-10 levels were observed in patients achieving a rapid viral response (RVR) ( P < .0001), even in those with body mass index (BMI) ≥ 25 kg/m2 ( P = .004) and with baseline viral load ≥ 2 million IU/mL ( P = .001). Similarly, significantly lower IP-10 levels were observed in patients obtaining a sustained viral response (SVR) ( P = .0002), including those having higher BMI ( P < .05), higher viral load ( P = .0005), and both higher BMI and viral load ( P < .03). In multivariate logistic regression analyses, a low IP-10 value was independently predictive of both RVR and SVR. A baseline cutoff IP-10 value of 600 pg/mL yielded a negative predictive value (NPV) of 79% (19/24) for all genotype 1–infected patients, which was comparable with that observed using a reduction in HCV-RNA by at least 2 logs after 12 weeks of therapy (NPV 86%; 19/22); by combining the two, 30 of 38 patients (NPV 79%) potentially could have been spared unnecessary therapy. In patients having both higher BMI and viral load, cut-off levels of 150 and 600 pg/mL yielded a positive predictive value (PPV) of 71% and NPV of 100%, respectively. In conclusion , pretreatment IP-10 levels predict RVR and SVR in patients infected with HCV genotype 1, even in those with higher BMI and viral load. A substantial proportion of the latter patients may achieve SVR in spite of unfavorable baseline characteristics if their pretreatment IP-10 level is low. Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications
Liu, M., Guo, S., Hibbert, J. M., Jain, V., Singh, N., Wilson, N. O., & Stiles, J. K. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.06.001 · Cited by 751
Gane, E. J., Roberts, S. K., Stedman, C. A., Angus, P. W., Ritchie, B., Elston, R., Ipe, D., Morcos, P. N., Baher, L., Najera, I., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61384-0 · Cited by 335
Thomas, E., Gonzalez, V. D., Li, Q., Modi, A. A., Chen, W., Noureddin, M., Rotman, Y., & Liang, T. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.055 · Cited by 266
Metadata
- Authors
- Lagging, M., Romero, A. I., Westin, J., Norkrans, G., Dhillon, A. P., Pawlotsky, J.-M., Zeuzem, S., von Wagner, M., Negro, F., Schalm, S. W., Haagmans, B. L., Ferrari, C., Missale, G., Neumann, A. U., Verheij-Hart, E., & Hellstrand, K.
- Venue
- Hepatology
- Published
- 2006-12
- Volume
- 44
- Issue
- 6
- Pages
- 1617-1625
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2001360631
- Cited by
- 216
- References
- 0
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. https://app.cochat.ai/papers/10.1002/hep.21407
- The paper
- Lagging, M., Romero, A. I., Westin, J., Norkrans, G., Dhillon, A. P., Pawlotsky, J.-M., Zeuzem, S., von Wagner, M., Negro, F., Schalm, S. W., Haagmans, B. L., Ferrari, C., Missale, G., Neumann, A. U., Verheij-Hart, E., & Hellstrand, K. (2006). IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. https://doi.org/10.1002/hep.21407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.